Abstract
Angiogenesis is one of the most distinctive hallmarks of glioblastoma (GBM). The aim of this study is to assess the difference in terms of survival and safety between the 5mg/m2 and 10mg/m2 bevacizumab schedule in recurrent GBM.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
